By Gail Dutton When the FDA approved Genentech’s Herceptin in 2010, it became the first genetically targeted therapy for breast cancer. Today that tight targeting is becoming possible for other drugs and diseases, as pharmaceutical companies turn to big data to help with drug development. Big data is beginning to deliver on read »
